Witty David R, Bateson John H, Hervieu Guillaume J, Jeffrey Phillip, Johnson Christopher N, Muir Alison I, O'Hanlon Peter J, Stemp Geoffrey, Stevens Alex J, Thewlis Kevin M, Wilson Shelagh, Winborn Kim Y
GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK.
Bioorg Med Chem Lett. 2006 Sep 15;16(18):4865-71. doi: 10.1016/j.bmcl.2006.06.056. Epub 2006 Jul 12.
We report here the discovery of a class of MCH R1 ligands based on a biphenyl carboxamide template. A docked-in model is presented indicating key interactions in the putative binding site of the receptor. Parallel high throughput synthetic techniques were utilised to allow rapid exploration of the structure-activity relationship around this template, leading to compound SB-568849 which possessed good receptor affinity and selectivity. This compound proved to be an antagonist with stability in vivo, an acceptable brain-blood ratio and oral bioavailability.
我们在此报告基于联苯甲酰胺模板发现了一类MCH R1配体。展示了一个对接模型,表明了在受体假定结合位点中的关键相互作用。利用平行高通量合成技术,以便快速探索围绕该模板的构效关系,从而得到了具有良好受体亲和力和选择性的化合物SB - 568849。该化合物被证明是一种拮抗剂,在体内具有稳定性、可接受的脑血比和口服生物利用度。